Multiple SclerosisDHAMENCT07346703
Effects of DHA in Patients With Multiple Sclerosis
A study testing Docosahexaenoic Acid (DHA) Dietary Supplement and Sunflower Oil in people with Multiple Sclerosis and Performance Enhancement, run by Francisco Javier Martínez Noguera at 1 site in Spain.
Trial summary
This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Multiple Sclerosis, Performance Enhancement, Supplemental Nutrition Assistance Program Education
- What is being tested?
- Docosahexaenoic Acid (DHA) Dietary Supplement and Sunflower Oil
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteSpain
- Study dates
- Jan 2026to Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- The patient sample comes from the Multiple Sclerosis Association (AMDEM) of the Murcia region and the neurology department of the Ribera Salud Hospital in Molina de Segura. Patients diagnosed with multiple sclerosis according to the McDonald criteria, aged between 18 and 65 (approximately), who have not suffered any flare-ups in the previous month and who have a score of 0.00 to 6 on the Expanded Disability Status Scale (EDSS) and are able to activate the tibialis anterior muscle will be eligible for the study.
Who cannot join
- Not fulfilling the inclusion criteria.
- Having any problems performing the tests.
- Having any problems taking the supplement or placebo.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site
Research Center for High Performance Sport. Universidad Católica de Murcia
La Ñora, Murcia, 30830
About this study
Official title: Effects of Therapeutic Exercise and Long-term Docosahexaenoic Acid (DHA) Supplementation on Physical, Physiological, Motor, Mental, and Cognitive Variables in Patients With Multiple Sclerosis.
This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Participants, diagnosed according to the McDonald criteria, will undergo functional, cognitive, fatigue, and quality-of-life assessments through tools such as the EDSS, BRB-N, MFIS, EVA-f, and MSQoL-54. Physiological evaluations will include infrared thermography, isokinetic strength testing, perceived exertion (Modified Borg Scale), balance (Timed Up and Go), lower-limb power (Sit-to-Stand app), and handgrip strength. The study hypothesizes that this combined intervention will improve motor function, cognition, fatigue management, and overall quality of life by enhancing neuromuscular activation and metabolic efficiency.
Read the detailed description
Design
Randomized clinical trial.
Study Period
Two years: from January 2024 to January 2026.
Population Selection Reference Population
The study sample will be recruited from the Multiple Sclerosis Association (AMDEM) in the Region of Murcia and the Neurology Department of Hospital Ribera Salud in Molina de Segura.
Eligible participants will be patients diagnosed with multiple sclerosis (MS) according to the McDonald criteria, aged approximately 18 to 65 years, who have not experienced relapse episodes in the month prior to inclusion, and have an Expanded Disability Status Scale (EDSS) score between 0.0 and 6.0, as well as the ability to voluntarily activate the tibialis anterior muscle.
Sample Size
Given the characteristics of the study, the target sample size is at least 100 participants, divided into four groups (n ≈ 25 per group) according to treatment.
Participants will be randomly assigned to one of four groups, each following a different therapeutic protocol:
Group 1: therapeutic exercise protocol three times per week throughout the study + daily DHA supplementation (4 capsule/day).
Group 2: same exercise protocol + placebo capsule (sunflower oil) identical in appearance, color, and dosage.
Group 3: DHA supplementation only (4 capsule/day).
Group 4: placebo capsule only (sunflower oil), identical to intervention groups.
Statistical Design
A one-way or repeated-measures ANOVA will be used to test for statistically significant differences among three or more dependent samples.
Measurement time points will be defined as follows:
T0: baseline (pre-intervention).
T1: midpoint of the intervention (approximately 1.5 months after initiation).
T2: immediately after completing the 3-month intervention protocol.
T3: 3 months after the end of the intervention.
Data Collection Participant Characteristics
Sensitive data will be collected regarding:
Age, sex, height, weight, medication use, relapse episodes in the months prior to the study, disability status, disease condition, and cognitive function.
Additional psychophysical information will be gathered using validated questionnaires administered before and after the intervention:
Disability will be assessed using the Expanded Disability Status Scale (EDSS).
A score of 0.0 represents normal physical function without disability.
3-4 indicates mild impairment not limiting daily or work activities.
5-6 indicates moderate disability, typically able to walk but requiring assistance for about 100 meters at level 6.
7-9 represents severe impairment, often confined to a wheelchair or bed.
Cognitive function will be assessed using the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), a validated tool for MS. It includes tests of selective recall, the 7/24 spatial recall test, the controlled oral word association test, and the paced auditory serial addition test (PASAT).
Fatigue will be measured using the Modified Fatigue Impact Scale (MFIS), assessing the perceived impact of fatigue on cognitive (10 items), physical (10 items), and psychosocial (20 items) functioning. Responses range from 0 (no problem) to 4 (extreme problem), with a maximum score of 160.
Quality of life will be measured with the Multiple Sclerosis Quality of Life-54 (MSQoL-54), a validated MS-specific scale that evaluates symptom severity, walking ability, absenteeism due to health, hospitalization history, depressive symptoms, and disease duration.
Functional Assessments
Pre, during and post--intervention.
Infrared thermography will capture whole-body thermal images before, during, and after the intervention as a non-invasive, reliable, and cost-effective diagnostic tool. Measurements will be taken:
Pre and post--intervention.
The Modified Borg Scale will be used to adjust exercise load intensity, maintaining perceived exertion between 5-7. If the score falls below 5, resistance will be increased by adding up to 5 kg. This will be recorded in the final session of each week.
The EVA-f scale (adapted fatigue visual analogue scale) will be used to measure subjective fatigue perception (0 = no fatigue; 10 = extreme fatigue) at the end of each training session.
The Sit-to-Stand App Test will be used to assess lower-limb power through video-based analysis of standing-up movements, providing values for time, power, and velocity (pre- and post-protocol).
The Timed Up and Go (TUG) Test will assess balance and fall risk. Participants will stand up from a chair, walk 3 meters, turn around, return, and sit down again. Two repetitions per session will be performed with one-minute rest intervals.
Handgrip strength will be measured (pre- and post-intervention) to assess upper-limb muscle strength.
Isokinetic strength tests will evaluate lower-limb strength (pre- and post-intervention).
Laboratory Tests
Serum analyses will include measurement of interleukin-6,
Blood samples will be collected at four time points:
Pre, during and immediately post-intervention.
- Conditions
- Multiple Sclerosis, Performance Enhancement, Supplemental Nutrition Assistance Program Education, Strength Outcomes, Function Improvement, Intervention Study
- Being tested
- Docosahexaenoic Acid (DHA) Dietary Supplement, Sunflower Oil
- Keywords
- Multiple sclerosis, Omega-3, nutritional supplements
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Docosahexaenoic Acid (DHA) Dietary SupplementDietary supplement
Also called Omega-3
Subjects will take 2 g of DHA per day for 3 months.
Docosahexaenoic Acid (DHA) Dietary SupplementDietary supplement
Subjects will take 2 g of DHA per day + therapeutic exercise (3 times a week) for 3 months.
Sunflower OilDietary supplement
Also called Placebo
Subjects will take 2 g of placebo (sunflower oil) per day for 3 months.
Sunflower OilDietary supplement
Subjects will take 2 g of placebo per day + therapeutic exercise (3 times a week) for 3 months.
| Study group | Role | What they receive |
|---|---|---|
| DHA | Experimental | This group will take 2 g of DHA (4 capsules per day) for 3 months Receives: Dietary Supplement: Docosahexaenoic Acid (DHA) Dietary Supplement |
| DHA + therapeutic exercise | Experimental | This group will take 2 g of DHA (4 capsules per day) + therapeutic exercise for 3 months Receives: Dietary Supplement: Docosahexaenoic Acid (DHA) Dietary Supplement |
| Sunflower oil | Placebo comparator | This group will take a placebo (4 capsules per day) for 3 months. Receives: Dietary Supplement: Sunflower Oil |
| Sunflower oil + therapeutic exercise | Placebo comparator | This group will take a placebo (4 capsules per day) + therapeutic exercise for 3 months. Receives: Dietary Supplement: Sunflower Oil |
What is being measured
The primary outcome is the main question the study is designed to answer.
ISOKINETIC
Measurement of isokinetic strength in the right leg N/m
Measured: Throughout study completion, an average of 12 weeks
Secondary outcomes (11)
Modified Fatigue Impact Scale
Fatigue is assessed using the Modified Fatigue Impact Scale, which considers the perceived impact of fatigue on cognitive functioning (10 items), physical functioning (10 items) and psychosocial functioning (20 items). It is a self-administered instrument in which subjects are asked to rate the extent to which fatigue has caused them problems (0 = no problem to 4 = extreme problem, maximum score = 160).
Measured: Throughout study completion, an average of 12 weeks
MSQoL-54 - Walking Status
Description: Functional walking status assessed using the walking-related item of the MSQoL-54.
Unit of Measure: Categorical (able to walk without assistance / needs assistance / wheelchair dependent).
Measured: Throughout study completion, an average of 12 weeks
MSQoL-54 - Days Unable to Work or Attend School Due to Health
Description: Number of days participants were unable to work or attend school due to health problems during the previous month, assessed via MSQoL-54.
Unit of Measure: Days (0, 1-15, 16-30).
Measured: Throughout study completion, an average of 12 weeks
MSQoL-54 - Hospital Admission in the Previous Year
Description: Self-reported hospital admission related to health status in the previous year, assessed via MSQoL-54.
Unit of Measure: Binary (yes/no).
Measured: Throughout study completion, an average of 12 weeks
MSQoL-54 - Depressive Symptoms
Description: Presence of self-reported depressive symptoms assessed using the corresponding MSQoL-54 item.
Unit of Measure: Binary (yes/no).
Measured: Throughout study completion, an average of 12 weeks
THERMOGRAPHY
Thermography study to capture full-body thermal images will be performed using a Flir E75 camera. The temperature (°C) of the lower limbs will be evaluated by analyzing the images.
Measured: Pre, six weeks after the start and after the intervention (12 weeks)
SIT TO STAND TEST
The Sit to Stand app test will be performed and muscle power will be assessed using the application. This tool is based on video recording of the movement of getting up from a chair. The unit of measurement is meters/seconds.
Measured: Throughout study completion, an average of 12 weeks
TIME UP AND GO test
The Time Up and Go test will be implemented, which is a method of assessing balance ability consisting of several parts, where the patient starts sitting in a chair, then stands up and walks 3 metres, turns around to return to the chair and then sits down, measuring the time it takes to complete the task. Each measurement will be repeated twice with a one-minute rest in between. To perform this test, the patient needs good posture control, coordination and strength in the lower limbs, and balance, movement control and risk of falls are assessed. The unit of measurement is in seconds.
Measured: Throughout study completion, an average of 12 weeks
HAND GRIP
Hand grip to assess upper limb strength through pre- and post-treatment grip strength. The unit of measurement is the kilogram.
Measured: Throughout study completion, an average of 12 weeks
IL-6
Serum interleukin 6 levels will be determined by blood sampling performed by an experienced nurse and analyzed in our reference laboratory.
Measured: Pre, six weeks after the start and after the intervention (12 weeks)
MSQoL-54 - Multiple Sclerosis Disease Duration
Description: Duration of multiple sclerosis since diagnosis.
Unit of Measure: Years.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study startJan 2026 (estimated)
- Primary completionJun 2026 (estimated)
- Study completionJul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A randomized parallel study will be conducted in which 100 participants with multiple sclerosis will be divided into four groups: one group will take 2 g of DHA (4 capsules; n = 25), another group will take 2 g of DHA (4 capsules; n = 25) combined with therapeutic exercise, a third group will take placebo (4 capsules; n = 25), and a fourth group will take placebo (4 capsules; n = 25) combined with therapeutic exercise. All participants will complete the study. The duration of the intervention will be 3 months. DHA = docosahexaenoic acid. Placebo = sunflower oil.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Francisco Javier Martínez Noguera
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Francisco Javier Martínez Noguera, Universidad Católica San Antonio de Murcia
- Investigators
- Francisco Javier Martínez Noguera, Researcher-PhD, Study chair, Universidad Católica San Antonio de Murcia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07346703
- Sponsor's protocol ID
- CE072415
- Acronym
- DHAME
- Status last verified
- Dec 2025
- First submitted
- 28 Nov 2025
- Last updated
- 16 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Therapeutic Exercise and Long-term Docosahexaenoic Acid (DHA) Supplementation on Physical, Physiological, Motor, Mental, and Cognitive Variables in Patients With Multiple Sclerosis.
- ClinicalTrials.gov ID
- NCT07346703
- Acronym / sponsor ID
- DHAME / CE072415
- Conditions
- Multiple Sclerosis, Performance Enhancement, Supplemental Nutrition Assistance Program Education, Strength Outcomes, Function Improvement, Intervention Study
- Keywords
- Multiple sclerosis, Omega-3, nutritional supplements
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Francisco Javier Martínez NogueraUniversity, hospital or other
- Study start
- Jan 2026 (estimated)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Jul 2026 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Participants, diagnosed according to the McDonald criteria, will undergo functional, cognitive, fatigue, and quality-of-life assessments through tools such as the EDSS, BRB-N, MFIS, EVA-f, and MSQoL-54. Physiological evaluations will include infrared thermography, isokinetic strength testing, perceived exertion (Modified Borg Scale), balance (Timed Up and Go), lower-limb power (Sit-to-Stand app), and handgrip strength. The study hypothesizes that this combined intervention will improve motor function, cognition, fatigue management, and overall quality of life by enhancing neuromuscular activation and metabolic efficiency.
Detailed description
Design
Randomized clinical trial.
Study Period
Two years: from January 2024 to January 2026.
Population Selection Reference Population
The study sample will be recruited from the Multiple Sclerosis Association (AMDEM) in the Region of Murcia and the Neurology Department of Hospital Ribera Salud in Molina de Segura.
Eligible participants will be patients diagnosed with multiple sclerosis (MS) according to the McDonald criteria, aged approximately 18 to 65 years, who have not experienced relapse episodes in the month prior to inclusion, and have an Expanded Disability Status Scale (EDSS) score between 0.0 and 6.0, as well as the ability to voluntarily activate the tibialis anterior muscle.
Sample Size
Given the characteristics of the study, the target sample size is at least 100 participants, divided into four groups (n ≈ 25 per group) according to treatment.
Participants will be randomly assigned to one of four groups, each following a different therapeutic protocol:
Group 1: therapeutic exercise protocol three times per week throughout the study + daily DHA supplementation (4 capsule/day).
Group 2: same exercise protocol + placebo capsule (sunflower oil) identical in appearance, color, and dosage.
Group 3: DHA supplementation only (4 capsule/day).
Group 4: placebo capsule only (sunflower oil), identical to intervention groups.
Statistical Design
A one-way or repeated-measures ANOVA will be used to test for statistically significant differences among three or more dependent samples.
Measurement time points will be defined as follows:
T0: baseline (pre-intervention).
T1: midpoint of the intervention (approximately 1.5 months after initiation).
T2: immediately after completing the 3-month intervention protocol.
T3: 3 months after the end of the intervention.
Data Collection Participant Characteristics
Sensitive data will be collected regarding:
Age, sex, height, weight, medication use, relapse episodes in the months prior to the study, disability status, disease condition, and cognitive function.
Additional psychophysical information will be gathered using validated questionnaires administered before and after the intervention:
Disability will be assessed using the Expanded Disability Status Scale (EDSS).
A score of 0.0 represents normal physical function without disability.
3-4 indicates mild impairment not limiting daily or work activities.
5-6 indicates moderate disability, typically able to walk but requiring assistance for about 100 meters at level 6.
7-9 represents severe impairment, often confined to a wheelchair or bed.
Cognitive function will be assessed using the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), a validated tool for MS. It includes tests of selective recall, the 7/24 spatial recall test, the controlled oral word association test, and the paced auditory serial addition test (PASAT).
Fatigue will be measured using the Modified Fatigue Impact Scale (MFIS), assessing the perceived impact of fatigue on cognitive (10 items), physical (10 items), and psychosocial (20 items) functioning. Responses range from 0 (no problem) to 4 (extreme problem), with a maximum score of 160.
Quality of life will be measured with the Multiple Sclerosis Quality of Life-54 (MSQoL-54), a validated MS-specific scale that evaluates symptom severity, walking ability, absenteeism due to health, hospitalization history, depressive symptoms, and disease duration.
Functional Assessments
Pre, during and post--intervention.
Infrared thermography will capture whole-body thermal images before, during, and after the intervention as a non-invasive, reliable, and cost-effective diagnostic tool. Measurements will be taken:
Pre and post--intervention.
The Modified Borg Scale will be used to adjust exercise load intensity, maintaining perceived exertion between 5-7. If the score falls below 5, resistance will be increased by adding up to 5 kg. This will be recorded in the final session of each week.
The EVA-f scale (adapted fatigue visual analogue scale) will be used to measure subjective fatigue perception (0 = no fatigue; 10 = extreme fatigue) at the end of each training session.
The Sit-to-Stand App Test will be used to assess lower-limb power through video-based analysis of standing-up movements, providing values for time, power, and velocity (pre- and post-protocol).
The Timed Up and Go (TUG) Test will assess balance and fall risk. Participants will stand up from a chair, walk 3 meters, turn around, return, and sit down again. Two repetitions per session will be performed with one-minute rest intervals.
Handgrip strength will be measured (pre- and post-intervention) to assess upper-limb muscle strength.
Isokinetic strength tests will evaluate lower-limb strength (pre- and post-intervention).
Laboratory Tests
Serum analyses will include measurement of interleukin-6,
Blood samples will be collected at four time points:
Pre, during and immediately post-intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- A randomized parallel study will be conducted in which 100 participants with multiple sclerosis will be divided into four groups: one group will take 2 g of DHA (4 capsules; n = 25), another group will take 2 g of DHA (4 capsules; n = 25) combined with therapeutic exercise, a third group will take placebo (4 capsules; n = 25), and a fourth group will take placebo (4 capsules; n = 25) combined with therapeutic exercise. All participants will complete the study. The duration of the intervention will be 3 months. DHA = docosahexaenoic acid. Placebo = sunflower oil.
| Arm | Type | Receives |
|---|---|---|
| DHA | Experimental | Dietary Supplement: Docosahexaenoic Acid (DHA) Dietary SupplementThis group will take 2 g of DHA (4 capsules per day) for 3 months |
| DHA + therapeutic exercise | Experimental | Dietary Supplement: Docosahexaenoic Acid (DHA) Dietary SupplementThis group will take 2 g of DHA (4 capsules per day) + therapeutic exercise for 3 months |
| Sunflower oil | Placebo comparator | Dietary Supplement: Sunflower OilThis group will take a placebo (4 capsules per day) for 3 months. |
| Sunflower oil + therapeutic exercise | Placebo comparator | Dietary Supplement: Sunflower OilThis group will take a placebo (4 capsules per day) + therapeutic exercise for 3 months. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- The patient sample comes from the Multiple Sclerosis Association (AMDEM) of the Murcia region and the neurology department of the Ribera Salud Hospital in Molina de Segura. Patients diagnosed with multiple sclerosis according to the McDonald criteria, aged between 18 and 65 (approximately), who have not suffered any flare-ups in the previous month and who have a score of 0.00 to 6 on the Expanded Disability Status Scale (EDSS) and are able to activate the tibialis anterior muscle will be eligible for the study.
Key exclusion criteria (3 listed)
- Not fulfilling the inclusion criteria.
- Having any problems performing the tests.
- Having any problems taking the supplement or placebo.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Docosahexaenoic Acid (DHA) Dietary SupplementAlso: Omega-3Subjects will take 2 g of DHA per day for 3 months. | Dietary supplement | DHA |
| Docosahexaenoic Acid (DHA) Dietary SupplementSubjects will take 2 g of DHA per day + therapeutic exercise (3 times a week) for 3 months. | Dietary supplement | DHA + therapeutic exercise |
| Sunflower OilAlso: PlaceboSubjects will take 2 g of placebo (sunflower oil) per day for 3 months. | Dietary supplement | Sunflower oil |
| Sunflower OilSubjects will take 2 g of placebo per day + therapeutic exercise (3 times a week) for 3 months. | Dietary supplement | Sunflower oil + therapeutic exercise |
Primary outcome
ISOKINETIC
Time frame: Throughout study completion, an average of 12 weeks
Measurement of isokinetic strength in the right leg N/m
11 secondary outcomes
Modified Fatigue Impact Scale
Time frame: Throughout study completion, an average of 12 weeks
MSQoL-54 - Walking Status
Time frame: Throughout study completion, an average of 12 weeks
MSQoL-54 - Days Unable to Work or Attend School Due to Health
Time frame: Throughout study completion, an average of 12 weeks
MSQoL-54 - Hospital Admission in the Previous Year
Time frame: Throughout study completion, an average of 12 weeks
MSQoL-54 - Depressive Symptoms
Time frame: Throughout study completion, an average of 12 weeks
THERMOGRAPHY
Time frame: Pre, six weeks after the start and after the intervention (12 weeks)
SIT TO STAND TEST
Time frame: Throughout study completion, an average of 12 weeks
TIME UP AND GO test
Time frame: Throughout study completion, an average of 12 weeks
HAND GRIP
Time frame: Throughout study completion, an average of 12 weeks
IL-6
Time frame: Pre, six weeks after the start and after the intervention (12 weeks)
MSQoL-54 - Multiple Sclerosis Disease Duration
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
- Research Center for High Performance Sport. Universidad Católica de Murcia.Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Francisco Javier Martínez Noguera, Researcher-PhD study chair
Universidad Católica San Antonio de Murcia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Docosahexaenoic Acid (DHA) Dietary Supplement and Sunflower Oil in people with Multiple Sclerosis and Performance Enhancement, run by Francisco Javier Martínez Noguera at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ISOKINETIC (time frame: Throughout study completion, an average of 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.